Brought to you by 
Sanofi and Lead Pharma develop ROR gamma (t) therapies for autoimmune diseases
01 Feb 2023
Executive Summary
Sanofi teamed up with Lead Pharma to develop inhibitors of the nuclear receptor retinoic acid receptor-related orphan receptor gamma (ROR gamma (t)) to treat a variety of autoimmune diseases. Sanofi gets global rights to resulting compounds.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi and Lead Pharma develop ROR gamma (t) therapies for autoimmune diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice